Immunology Drugs Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Immunology Drugs Market Size, Share & Trends Analysis Report By Drug Type, By Therapy Area, By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2031

Report Overview

The Global Immunology Drugs Market reached US$ 91.97 billion in 2023 and is expected to reach US$ 148.62 billion by 2031, growing at a CAGR of 6.35% during the forecast period 2024-2031.

Immunology is a science that deals with the immune system and the cell-mediated and humoral aspects of immunity and immune responses.

Immunology drugs are medications that can either boost or weaken the immune system, changing the immunological response. They fight against infections and are used in the prevention and treatment of certain illnesses.  Medications used for immunosuppression to avoid graft rejection are considered immunologic agents.

The market is being driven primarily by the following factors such as an increase in the rising prevalence of autoimmune diseases, multiple FDA approvals, increased research to produce novel medications, and the growing requirement for biosimilars and monoclonal antibodies.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Growing Demand for Monoclonal Antibodies and Biosimilars

The demand for the global immunology drugs market is driven by multiple factors. Monoclonal antibodies are used in the treatment of various types of cancer and immunological indications.  Monoclonal antibodies (MABs) are a type of targeted drug therapy. 

These immunology drugs recognize and find specific proteins in cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing. The biosimilar will be used to treat 8 indications, including rheumatoid arthritis, inflammatory bowel disease, and plaque psoriasis. 

Moreover, key players in the market launching new innovative drugs and approvals would propel this market. For instance, in May 2023 Antengene Corporation Limited, announced the U.S. Food and Drug Administration (FDA) granted approval for the investigational novel drug (IND) for the first-in-class anti-CD24 monoclonal antibody compound ATG-031 Phase I study used in the treatment for oncology and hematology.

As per the Center for Biosimilars at AJMC, 4 adalimumab biosimilar products including  Cyltezo, Yusimry, Hadlima, and Hyrimoz in the United States were first introduced in July 2023.

Also, in July 2023, a biosimilar to AbbVie's Humira (adalimumab), Sandoz, a Novartis business, announced the U.S. launch of its citrate-free high-concentration formulation (HCF) of Hyrimoz (adalimumab-day). All indications, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa that are no longer covered by the reference medicine regulatory exclusivity are approved for treatment with Hyrimoz.

Restraints

Factors such as the high cost  & side effects associated with treatment, stringent regulatory policies, lack of skilled professionals, complex reimbursement systems, and lack of awareness about drugs are expected to hamper the market.

Segment Analysis

The global immunology drugs market is segmented based on drug type, therapy area, distribution channel, and region.

The monoclonal antibodies segment accounted for approximately 56.3% of the  global immunology drugs market share

The monoclonal antibodies segment is expected to hold the largest market share over the forecast period. Due to the rise in cancer cases and the increasing popularity of monoclonal antibody therapies in cancer treatment.

Moreover, key players in the industry such as partnerships and collaborations, product launches, and clinical trials data would propel this market. In February 2024, AbbVie and OSE Immunotherapeutics announced a partnership to develop a novel monoclonal antibody for the treatment of chronic inflammation.

Similarly, in April 2023, researchers at the Johns Hopkins Kimmel Cancer Center as well as its Bloomberg Kimmel Institute for Cancer Immunotherapy are currently conducting a phase 2 study to determine the safety of enoblituzumab, a monoclonal antibody, in men with aggressive prostate cancer. If successful, the study could lead to clinical efficacy against cancers of all types.  

Also, in February 2023, Elranatamab, a B-cell maturation antigen bispecific antibody (BsAb) under research that is directed towards CD3 and manufactured by Pfizer, recently announced about Priority Review grant by the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) for treating patients having relapsed or refractory multiple myeloma (RRMM). 

Geographical Analysis

North America accounted for approximately 41.7% of the global immunology drugs  market share 

North America region is expected to hold the largest market share over the forecast period. In this region, the United States is expected to have a major share due to its highly developed pharmaceutical R&D sector and key companies operating in the market studied.

The increasing number of cancer cases is creating tremendous opportunities for market players. The major market players are focusing on R&D activities to launch new and reliable treatments. For instance, in October 2022, the FDA approved a combination of the immunotherapy drugs durvalumab (Imfinzi) and tremelimumab (Imjudo) for people with unresectable hepatocellular cancer, the most common type of liver cancer.

Additionally, new product launches in the area of immunology drugs are propelling market growth. For instance, in November 2022, DuoBody-PD-L1x4-1BB (GEN1046) monoclonal antibody was co-developed by Genmab and BioNTech for Solid tumors in Phase 1/2 and Non-small cell lung cancer in Phase 2.

COVID-19 Impact Analysis  

The COVID-19 pandemic positively impacted the global immunology drugs market. During the pandemic, immunology research was boosted during the pandemic to comprehend the way COVID-19 affects immunity and deal with its devastating impacts. In 2021, The University of Oxford Immunology Network focused on humoral immunity, deep phenotyping, cell immunity, and the inflammatory response during the COVID-19 period. 

In addition, during the pandemic, studies on immunology drugs for COVID-19 expanded. To treat COVID-19,  immunomodulatory drugs such as BTK and JAK inhibitors have been investigated. The rising research on immunology drugs to combat the COVID-19 disease fueled the market's growth. However, currently, the market has reached its pre-pandemic nature and is expected to witness significant growth over the forecast period.

Market Segmentation

By Drug Type

• Monoclonal Antibodies
• Antibody Drug Conjugates
• Immunosuppressive medication
• Interferon and Cytokine Therapies
• Others

By Therapy Area

•  Rheumatoid Arthritis
• Psoriasis
•  Inflammatory Bowel Disease
•  Graft Versus Host Disease
•  Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America

• U.S.
• Canada
• Mexico

• Europe

• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe

• South America

• Brazil
• Argentina
• Rest of South America

• Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

• Middle East and Africa

Competitive Landscape

The major global players in the immunology drugs market include Eli-Lilly, Novartis, AbbVie, Sun Pharmaceuticals, Johnson &Johnson, ViiV Healthcare, Bristol-Myers Squibb, Gilead, Pfizer Inc, and GlaxoSmithKline plc among others.

Key Developments

• On May 15, 2024,  Blackstone announced the launch of the Blackstone Life Sciences portfolio company Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation. 
• On April 22, 2024, ImmunityBio, Inc. an immunotherapy company, announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. 
•  On February 2, 2024, AbbVie raises the 2027 sales forecast for new immunology drugs to $27 billion. 

Why Purchase the Report?

• To visualize the global immunology drugs market segmentation based on drug type, therapy area, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global immunology drugs market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global immunology drugs market report would provide approximately 62 tables, 56 figures, and 182 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies